bendamustine hydrochloride has been researched along with pyrazines in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (25.00) | 29.6817 |
| 2010's | 24 (66.67) | 24.3611 |
| 2020's | 3 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cheson, BD | 4 |
| Baumann, P; Bumeder, I; Emmerich, B; Meinhardt, G; Schmidmaier, R; Straka, C | 1 |
| Gertz, MA | 1 |
| Bruns, I; Czibere, A; Fenk, B; Fenk, R; Graef, T; Haas, R; Kobbe, G; Michael, M; Neumann, F; Zohren, F | 1 |
| Friedberg, JW; Hagemeister, FB; Leonard, JP; Levine, AM | 1 |
| Bargetzi, M; Heizmann, M; Kotrubczik, N; Moosmann, P; Wernli, M | 1 |
| Stewart, AK | 1 |
| Kahl, BS | 1 |
| Rummel, M | 1 |
| Armitage, JO; Bernstein, SH; Blumel, S; Fisher, RI; Friedberg, JW; Grant, S; Kelly, JL; Leonard, JP; Liesveld, J; Peterson, D; Proia, NK; Rich, L; Vose, JM; Young, F | 1 |
| Amin, B; Cashen, AF; Cheson, BD; Fowler, N; Jacobs, SA; Kahl, BS; Lee, P; Letzer, J; Matous, JV; Parasuraman, S; Rosen, P; Saleh, A; Shi, H; Smith, S; Williams, ME | 1 |
| Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Ogura, M | 1 |
| Berenson, JR; Bessudo, A; Boccia, RV; Gorak, EJ; Gravenor, DS; Kewalramani, T; Mayo, D; Nassir, Y; Noga, SJ; Patel-Donnelly, D; Siegel, RS; Swift, RA; Yellin, O | 1 |
| Ali, HA; Aßmann, M; Becker, C; Bourgeois, M; Edelmann, T; Hensel, G; Heyn, S; Hoffmann, FA; Hurtz, HJ; Jäkel, N; Krahl, R; Löschcke, K; Mohren, M; Moll, B; Niederwieser, D; Pönisch, W; Rohrberg, R; Schmalfeld, M; Schönfelder, U; Schwarzer, A; Wagner, I; Zehrfeld, T | 1 |
| Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
| Giannotta, A; Guaragna, G; Mele, G; Melpignano, A; Quarta, G; Spina, A | 1 |
| Al Ali, H; Andrea, M; Bachmann, A; Becker, C; Bourgeois, M; Edelmann, T; Egert, M; Fricke, S; Heyn, S; Hoffmann, FA; Krahl, R; Kreibich, U; Lindner, T; Moll, B; Niederwieser, D; Petros, S; Pönisch, W; Remane, Y; Schliwa, T; Schmalfeld, M; Schwarzer, A; Stiegler, R; Vucinic, V; Weidhase, L | 1 |
| Adam, Z; Greil, R; Kasparu, H; Leitgeb, C; Linkesch, W; Ludwig, H; Pour, L; Rauch, E; Seebacher, A; Weißmann, A; Zojer, N | 1 |
| Lentzsch, S | 1 |
| Adam, Z; Krejčí, M; Pour, L; Ševčíková, E | 1 |
| Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T | 1 |
| Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Aujesky, D; Oestmann, A | 1 |
| Chim, CS; Wong, KY | 1 |
| Nakaseko, C | 1 |
| Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K | 1 |
| Anglaret, B; Avet-Loiseau, H; Banos, A; Benboubker, L; Benramdane, R; Casassus, P; Chaleteix, C; Cony-Makhoul, P; Decaux, O; Dejoie, T; Dib, M; Fitoussi, O; Fontan, J; Garderet, L; Hulin, C; Jardel, H; Kolb, B; Leleu, X; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Pétillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Traullé, C; Vilque, JP | 1 |
| Treon, SP | 1 |
| Avery, E; Campbell, P; de la Serna, J; Dolan, S; Ghia, P; Illes, A; Jacob, A; Jurczak, W; Kaplan, P; Kozak, T; Kraychok, I; Lee, JH; Liang, W; Lysak, D; Musuraca, G; Patel, P; Pluta, A; Quah, C; Simkovic, M; Wach, M | 1 |
| Castillo, JJ; Sarosiek, S; Treon, SP | 1 |
| Al-Sawaf, O; Böttcher, S; Brüggemann, M; Cramer, P; Dreger, P; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Giza, A; Hallek, M; Kneba, M; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Schetelig, J; Schilhabel, A; Schneider, C; Stilgenbauer, S; Tausch, E; Zhang, C | 1 |
11 review(s) available for bendamustine hydrochloride and pyrazines
| Article | Year |
|---|---|
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
Combination treatment approaches and novel therapies for lymphoma.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cancer Vaccines; Cytokines; Humans; Immunologic Factors; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Stem Cell Transplantation | 2007 |
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Nitrogen Mustard Compounds; Pyrazines; Vidarabine | 2009 |
Novel therapies for relapsed myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drugs, Investigational; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mice; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Salvage Therapy; Thalidomide | 2009 |
Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Sirolimus; Survival Analysis; Treatment Outcome | 2009 |
Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.
Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Rituximab; Thalidomide | 2010 |
New agents in follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Follicular; Mice; Nitrogen Mustard Compounds; Phosphotransferases; Protein Kinase Inhibitors; Pyrazines; Recurrence; Remission Induction; Rituximab; Signal Transduction; Thalidomide; Tumor Microenvironment | 2011 |
[Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2014 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
[Treatment of transplant-eligible symptomatic multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning | 2014 |
How to Sequence Therapies in Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Waldenstrom Macroglobulinemia | 2021 |
10 trial(s) available for bendamustine hydrochloride and pyrazines
| Article | Year |
|---|---|
First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma.
Topics: Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy; Simvastatin | 2007 |
Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cohort Studies; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2010 |
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab | 2011 |
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Treatment Outcome | 2013 |
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Survival Analysis | 2014 |
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Pyrazines; Survival Rate | 2015 |
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Purines; Pyrazines; Quinazolinones; Rituximab | 2020 |
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cytoreduction Surgical Procedures; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides | 2022 |
15 other study(ies) available for bendamustine hydrochloride and pyrazines
| Article | Year |
|---|---|
What is the correct philosophy for the treatment of multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines | 2007 |
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy | 2007 |
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vincristine | 2008 |
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting | 2012 |
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Recurrence; Retrospective Studies | 2013 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies | 2013 |
Bendamustine: the remedy that came in from the cold.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines | 2014 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
[Hyperammonemic encephalopathy in multiple myeloma].
Topics: Alkalosis, Respiratory; Ammonia; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Dyspnea; Fatal Outcome; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Rett Syndrome | 2014 |
Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunoglobulin G; Karyotyping; Male; Middle Aged; Multiple Myeloma; Mutation; Nitrogen Mustard Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; ras Proteins; Recurrence; Signal Transduction; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2014 |
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Failure | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |